- BNF:
- 8.1.5
- Status:
- Do Not Prescribe (DNP), Red
- Decision Date:
- None
Comments
RED:
- NICE TA228: Bortezomib and thalidomide for the first-line treatment of multiple myeloma. A recommended option only if thalidomide not tolerated or suitable. (Decision date - August 2011).
- NICE TA311: Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation. (Decision date - May 2014).
- NICE TA370: Bortezomib for previously untreated mantle cell lymphoma. (Decision date - January 2016).
Do Not Prescribe (DNP):
- NICE TA453: Bortezomib for treating multiple myeloma after second or subsequent relapse. (Terminated appraisal). (Decision date - August 2017).
NHS England drug. To be used in line with NHS England commissioning intentions.
Do Not Prescribe (DNP) Drug Classifications
- 6: Have NICE guidance that recommends they should not be used
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
- 4: Specifically designated as “hospital only” by product licence or by DH/NICE
- 8. NHS England commissioned – to be used in line with NHSE commissioning intentions
search again
